Search

Your search keyword '"de Gonzalez, A. Berrington"' showing total 6 results
Start Over Author "de Gonzalez, A. Berrington" Topic breast cancer
6 results on '"de Gonzalez, A. Berrington"'

2. Polygenic score distribution differences across European ancestry populations: implications for breast cancer risk prediction

Author

Yiangou, Kristia, Mavaddat, Nasim, Dennis, Joe, Zanti, Maria, Wang, Qin, Bolla, Manjeet K., Abubakar, Mustapha, Ahearn, Thomas U., Andrulis, Irene L., Anton-Culver, Hoda, Antonenkova, Natalia N., Arndt, Volker, Aronson, Kristan J., Augustinsson, Annelie, Baten, Adinda, Behrens, Sabine, Bermisheva, Marina, de Gonzalez, Amy Berrington, Białkowska, Katarzyna, Boddicker, Nicholas, Bodelon, Clara, Bogdanova, Natalia V., Bojesen, Stig E., Brantley, Kristen D., Brauch, Hiltrud, Brenner, Hermann, Camp, Nicola J., Canzian, Federico, Castelao, Jose E., Cessna, Melissa H., Chang-Claude, Jenny, Chenevix-Trench, Georgia, Chung, Wendy K., Colonna, Sarah V., Couch, Fergus J., Cox, Angela, Cross, Simon S., Czene, Kamila, Daly, Mary B., Devilee, Peter, Dörk, Thilo, Dunning, Alison M., Eccles, Diana M., Eliassen, A. Heather, Engel, Christoph, Eriksson, Mikael, Evans, D. Gareth, Fasching, Peter A., Fletcher, Olivia, Flyger, Henrik, Fritschi, Lin, Gago-Dominguez, Manuela, Gentry-Maharaj, Aleksandra, González-Neira, Anna, Guénel, Pascal, Hahnen, Eric, Haiman, Christopher A., Hamann, Ute, Hartikainen, Jaana M., Ho, Vikki, Hodge, James, Hollestelle, Antoinette, Honisch, Ellen, Hooning, Maartje J., Hoppe, Reiner, Hopper, John L., Howell, Sacha, Howell, Anthony, Jakovchevska, Simona, Jakubowska, Anna, Jernström, Helena, Johnson, Nichola, Kaaks, Rudolf, Khusnutdinova, Elza K., Kitahara, Cari M., Koutros, Stella, Kristensen, Vessela N., Lacey, James V., Lambrechts, Diether, Lejbkowicz, Flavio, Lindblom, Annika, Lush, Michael, Mannermaa, Arto, Mavroudis, Dimitrios, Menon, Usha, Murphy, Rachel A., Nevanlinna, Heli, Obi, Nadia, Offit, Kenneth, Park-Simon, Tjoung-Won, Patel, Alpa V., Peng, Cheng, Peterlongo, Paolo, Pita, Guillermo, Plaseska-Karanfilska, Dijana, Pylkäs, Katri, Radice, Paolo, Rashid, Muhammad U., Rennert, Gad, Roberts, Eleanor, Rodriguez, Juan, Romero, Atocha, Rosenberg, Efraim H., Saloustros, Emmanouil, Sandler, Dale P., Sawyer, Elinor J., Schmutzler, Rita K., Scott, Christopher G., Shu, Xiao-Ou, Southey, Melissa C., Stone, Jennifer, Taylor, Jack A., Teras, Lauren R., van de Beek, Irma, Willett, Walter, Winqvist, Robert, Zheng, Wei, Vachon, Celine M., Schmidt, Marjanka K., Hall, Per, MacInnis, Robert J., Milne, Roger L., Pharoah, Paul D. P., Simard, Jacques, Antoniou, Antonis C., Easton, Douglas F., and Michailidou, Kyriaki

Published
2024
Full Text
View/download PDF

6. Estimated Risk of Radiation-Induced Breast Cancer From Mammographic Screening for Young BRCA Mutation Carriers.

Author

De Gonzalez, Amy Berrington, Berg, Christine D., Visvanathan, Kala, and Robson, Mark

Subjects
*RADIATION carcinogenesis, *MAMMOGRAMS, *BREAST cancer, *GENETICS, *CONFIDENCE intervals, *GENETIC mutation
Abstract

BRCA mutation carriers are recommended to start mammographic screening for breast cancer as early as age 25-30 years. We used an excess relative risk model (based on a pooled analysis of three cohorts with 7600 subjects who received radiation exposure) to estimate the lifetime risk of radiation-induced breast cancer from five annual mammographic screenings in young (<40 years) BRCA mutation carriers. We then estimated the reduction in breast cancer mortality required to out- weigh the radiation risk. Breast cancer rates for mutation carriers were based on a pooled analysis of 22 pedigree studies with 8139 subjects. For BRCAI mutation carriers, the estimated lifetime risk of radiation-induced breast cancer mortality per 10000 women resulting from annual mammography was 26 (95% confidence interval [li = 14 to 49) for screening at age 25-29 years, 20 (95% Cl = 11 to 39) for screening at age 30-34 years. and 13 (95% Cl = 7 to 23) for screening at age 35-39 years. To outweigh these risks, screening would have to reduce breast cancer mortality by 51% (95% Cl = 27% to 96%) at age 25-29 years, by 12% (95% Cl = 6% to 23%) at age 30-34 years, and by 4% (95% Cl = 2% to 7%) at age 35-39 years; estimates were similar for BRCA2 mutation carriers. If we assume that the mortality reduction from mammography is 15%-25% or less for young women, these results suggest that there would be no net benefit from annual mammographic screening of BRCA mutation carriers at age 25-29 years; the net benefit would be zero or small at age 30-34 years, but there should be some net benefit at age 35 or older. These results depend on a number of assumptions due to the absence of empiric data. The impact of varying these assumptions was therefore examined. [ABSTRACT FROM AUTHOR]

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results